dr-matossian

CLINICAL STUDIES:

2015
Safety and efficacy of OTXDP in post-op pain and inflammation in cataract surgery (Ocular Therapeutix)

2015
Comparison of the safety and efficacy of Ta4 to placebo for the treatment of neurotrophic keratits (ORA)

2015
A registry evaluation of ReSure® Sealant for specified adverse ocular events after sealing corneal incisions in patients undergoing clear cataract surgery (Ocular Therapeutix)

2015
Investigation of trabecular micro-bypass stent system in conjunction with cataract surgery (Glaukos)

2014
A Phase 3, Multi-Center, Double-Masked, Placibo-Controlled, Randomized Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placibo in Subjects with Dry Eye and History of Artificial Tear Use (Shire)

2014
Functional Benefit of the AcrySof Natural Chromophore post-market study (Alcon)

2014
Lenstec HD and HDO IOLs with Monte Carlo Application

2014
IPL Study with Duke Eye Center

2014
Abbott Medical Optics Tecnis Toric 1-piece IOL registry

2014
Ocular Theraputix evaluation of ReSure® Sealant in high risk patients

2014
Bausch + Lomb Lotemax loteprednol etabonate ophthalmic suspension ophthalmic gel versus vehicle gel in treatment of inflammation/pain following cataract surgery

2014
Abbott Medical Optics use of WHITESTAR Signature® with two different tips in cataract surgery

2014
Hoffer H5 Axial Length

2014
Icon Phase 3 Treatment of Post-Op Inflammation in Cataract Study

2014
Physician Recommended Nutriceuticals Dry Eye Study

2013
Alcon Research Ltd, Effect of blue light filtration on visual performance, protocol A01311 version 1.0

2013
Lenstec HDO IOL analyzing Dysphotopsia in Pseudophakic patients

2013
Adenovirus Rapid Pathogen Screening Study

2013
SONATA, a Phase III, multi-center, randomized, double-masked and placebo-controlled study evaluating the safety of a 5.0% concentration of Lifitegrast Ophthalmic Solution compared to placebo in subjects with dry eye

2013
Impact of tear osmolarity on pre-surgical calculations in cataract surgery

2013
The influence of the PRN Dry Eye Omega 3 nutritional regimen in osmolarity in cases of occasional dry eye.

2013
Sarcode Bioscience, Inc., Sonata Clinical Trial, Dry Eye

2013
Internal study on Restasis® Cyclosporine Ophthalmic Emulsion BID alone, with Lotemax induction, and with Bromday induction

2012
Mixing and matching a toric IOL in the eye with the greater astigmatism and using a blended min-mono approach with an aspheric mono-focal IOL plus an LRI to correct the spherical and cylinder errors in the eye with the lesser astigmatism.

2012
Conversion rates for premium services (LRI, Toric and presbyopia correcting IOLs) based on gender and age.

2012
The use of an equibiconvex quarter diopter aspheric IOL for cataract surgery to measure uncorrected intermediate vision.

2011
Alcon Pharmaceuticals – Difluprednate Ophthalmic Emulsion 0.05% for post operative inflammation and pain QID vs. BID when paired with an NSAID

2011
Abbot Medical Optics — Evaluation of RevitaLens for soft contact lens care

2010
Abbot Medical Optics – Evaluation of Blink Artificial Tears on its effectiveness for the symptoms of dry eye syndrome

2010
Ista Pharmaceuticals – 6 Month Dry Eye Study

2009
Sanofi-Aventis – Providing ophthalmologic evaluations for a study in which Tamaris, a vascular endothelial growth factor, is being used to help peripheral blood vessels. The study requires dilated ophthalmic funduscopic exams to participants on scheduled intervals.

2009
Ista Pharmaceuticals — Efficacy and Safety of Bromfenac Ophthalmic Solution QD vs. Placebo QD for Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery

2008
Allergan, Inc. – Phase IV – A Multi-Center, investigator-masked, randomzed, parallel study to compare the IOP lowering efficacy and safety of Combigan (fixed combination of 0.2% Brimonidine Tartrte and 0.5% Timolol Maleate) with Timolol (0.5% Timolol Maleate), when each is used as adjunctive therapy to Xalatan (0.005% Latanoprost) in subjects with Open-Angle Glaucoma and Ocular Hypertension.

2008
Ista Pharmaceuticals – Phase II – A Multi-Center, Double Blind, Vehicle-Controlled, Randomized Study of Ecabet Ophthalmic Solution in Patients with Dry Eye Disease

2007
Allergan, Inc. – Phase IV – A Multicenter, Masked Evaluation of Ocular Surface Tolerability Associated with Bimatoprost 0.03%, Travoprost 0.004% (BAK free) or Latanoprost 0.005% Therapy in Patients with Glaucoma or Ocular Hypertension.

2005 – 2006
Alcon Pharmaceutical, Travatan dosing aid study

2004
Wills Eye Hospital – Internet Based Study, Is One of Two Topical Prostaglandin Analogues Significantly More Tolerable Than the Other: Bimatroprost v. Latanoprost